The Aspen Ovestin sale will transfer European commercial rights to Ennogen Healthcare International for €197 million, while Aspen retains manufacturing and supply contracts. Wholly owned subsidiary Aspen Global will sell the commercialisation rights and associated intellectual property. The price equates to approximately R3.7 billion, with related inventory adding an estimated €4 million. However, completion depends on Ennogen’s funding arrangements becoming…
Aspen Sells European Ovestin Rights, Retains Supply Role
